Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TxCell appoints new CEO

This article was originally published in Scrip

Executive Summary

French biotech company TxCell, which develops cell-based therapies for severe chronic inflammatory diseases, has appointed Dr François Meyer as chief executive officer. Dr Meyer has held senior positions at Ciba-Geigy Pharma, Sandoz Pharma, Gencell and Aventis Pharma, and until 2006 served as CEO of Centelion. Dr Meyer joins as TxCell – a spin-off of the French National Institute for Health and Medical Research (Inserm) – prepares to move two product candidates through clinical trials: Phase IIb trials for refractory Crohn's disease and Phase I/II trials for refractory rheumatoid arthritis respectively.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel